The rise of innovative new therapeutic interventions means that payers need more information than ever to properly assess treatments, as well as compare them with existing methods of care. They also can benefit from collaborations with manufacturers, including on innovative pricing models. Precision's Reta Mourad joins other experts for a discussion of the opportunities and challenges facing payers as they confront antiquated reimbursement models and work to develop new payment models that include therapeutic value assessments.

LEARN MORE

Pharmaceutical manufacturers have accelerated innovation to create vaccines in record time, yet the US is lagging in leveraging effective messages to generate enthusiasm for COVID-19 vaccine adoption. Precision's Maureen Hennessey and Pam Caputo discuss how using the sacred patient-clinician relationship can help combat the infodemic of vaccine misinformation and disinformation.

LEARN MORE

In an October 2020 healthcare industry report, the authors projected that biosimilars could hit $80 billion in aggregate sales and provide savings in excess of $100 billion in aggregate over the next five years. Precision's Dan Danielson joins other industry experts to discuss the impact of biosimilars in 2020 and the forecast for the biosimilars landscape going forward.

LEARN MORE

While the COVID-19 pandemic seems likely to remain the dominant headline in 2021, a host of other potential occurrences could have big impacts this year. Precision's Dan Danielson joins a variety of industry experts to discuss what's ahead in 2021 for healthcare and pharma beyond the pandemic.

LEARN MORE

Recent reforms on price transparency will substantially increase payers' workloads. The Trump administration and CMS recently released a final rule that will require payers to post documents that include in-network and out-of-network provider rates and in-network drug prices starting in 2022. And in 2023, private insurers will be required to provide negotiated provider cost-sharing estimates and up-front prices to members. 

LEARN MORE

Leadership teams from the 2020 Manny Award winners and finalists participated in a comprehensive Q&A forum on a variety of healthcare industry themes and trends.

LEARN MORE

LEADING BIO-ENGINEERING AND MANUFACTURING SERVICES FIRM CATALYZES THE LAUNCH OF PRECISION’S CELL AND GENE THERAPY OFFERING—'PRECISION ADVANCE’—ADDRESSING THE UNIQUE CHALLENGES OF CELL & GENE THERAPY INNOVATORS, FROM DEVELOPMENT THROUGH COMMERCIALIZATION

LEARN MORE

The National Comprehensive Cancer Network (NCCN) recommended zanubrutinib, approved by the FDA for the treatment of adult patients with mantle cell lymphoma (MCL), for treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). The AJMC asked Precision's Erin Lopata to weigh in on how to respond when a drug is added to NCCN guidelines before the FDA approves the indication.

LEARN MORE

The Administration's recently released final rule on transparency in healthcare coverage is set to take effect January 1, 2023. The rule aims to provide increased visibility into the cost of care for treatments and procedures and to support cost-conscious decisions about healthcare services. Precision's Erin Lopata provides an overview of what you need to know now.

LEARN MORE

Update on HHS drug pricing rules: An HHS final rule targeting Medicare Part D rebates was issued on November 30, 2020. Unlike the interim rule, the final rule includes only rebates in Part D, not Medicaid managed care, and it pushes back implementation from Jan. 1, 2020, to Jan. 1, 2022. Comments on the interim final rule following the Most Favored Nation model are due by Jan. 26, 2021. Precision's Andrew Cournoyer and Ryan Cox weigh in on the problems and concerns with both rules.

LEARN MORE